Navigation Links
Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV
Date:9/14/2009

PRINCETON, N.J. and SAN DIEGO, Sept. 14 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers. TBR-652, a CCR5 antagonist under investigation for the treatment of HIV, was evaluated at doses ranging from 25 mg once daily (QD) to 200 mg QD after a high fat meal. Pharmacokinetic parameters were measured on Days 1 and 10, while safety and tolerability were evaluated throughout the 10 day study. The results of the study demonstrate TBR-652 was well tolerated in all groups. TBR-652 reached maximum plasma exposure 3-6 hours post dose on Days 1 and 10. Mean plasma half-life ranged from 40 to 45 hours, supporting once daily dosing. Exposure pharmacokinetic measures were greater than the therapeutic level projected from in vitro studies of TBR-652.

"This Phase I study provides further clinical support for the continued development of TBR-652 in the treatment of HIV. We are very encouraged by the excellent exposure results from the study and look forward to results from ongoing trials," said James Sapirstein, CEO.

These data were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 12-15, 2009 in San Francisco, California. The poster presentation can be viewed at www.tobiratherapeutics.com.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

    Contact:
    Tobira Therapeutics Inc.
    Antoinette Bobbitt Tobira Therapeutics Inc.
    abobbitt@tobiratherapeutics.com
    Tel: 609-897-1102
    www.tobiratherapeutics.com


'/>"/>
SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
2. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
3. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics Board of Directors as Chair
6. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
7. PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
8. /C O R R E C T I O N -- Clinical Therapeutics/
9. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
11. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):